Showing 1 - 5 results of 5 for search 'Petra Rietschel', query time: 0.03s Refine Results
  1. 1
    600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1

    600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1 by Mustafa Ozguroglu, Saadettin Kilickap, Igor Bondarenko, Ahmet Sezer, Mahmut Gümüş, Miranda Gogishvili, Xuanyao He, Giuseppe Gullo, Petra Rietschel, Ruben GW Quek

    Published 2023-11-01
    Article
  2. 2
    Machine learning models for identifying predictors of clinical outcomes with first-line immune checkpoint inhibitor therapy in advanced non-small cell lung cancer

    Machine learning models for identifying predictors of clinical outcomes with first-line immune checkpoint inhibitor therapy in advanced non-small cell lung cancer by Ying Li, Matthew Brendel, Ning Wu, Wenzhen Ge, Hao Zhang, Petra Rietschel, Ruben G. W. Quek, Jean-Francois Pouliot, Fei Wang, James Harnett

    Published 2022-10-01
    Get full text
    Article
  3. 3
    Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%

    Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50% by Nick Freemantle, Yingxin Xu, Florence R. Wilson, Patricia Guyot, Chieh-I Chen, Sam Keeping, Gerasimos Konidaris, Keith Chan, Andreas Kuznik, Kokuvi Atsou, Emily Glowienka, Jean-Francois Pouliot, Giuseppe Gullo, Petra Rietschel

    Published 2022-06-01
    Get full text
    Article
  4. 4
    597 Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen RNA vaccine BNT116 in patients with advanced non-small cell lung cancer

    597 Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen RNA vaccine BNT116 in patients with advanced non-small cell lung cancer by Patrick Forde, Neru Munshi, Ugur Sahin, Oezlem Tuereci, Akin Atmaca, Petra Rietschel, Dániel Deme, Bala Öven, Erdem Göker, Istvan Lang, Patrick Brück, Michael Wenger, Thomas Schell, Kezi Ünsal-Kaçmaz, Janet Markman, Huyuan Yang

    Published 2023-11-01
    Article
  5. 5
    Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer

    Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer by Josephine Louella Feliciano, Dylan McLoone, Yingxin Xu, Ruben G.W. Quek, Andreas Kuznik, Jean-Francois Pouliot, Giuseppe Gullo, Petra Rietschel, Patricia Guyot, Gerasimos Konidaris, Keith Chan, Sam Keeping, Florence R. Wilson, Nick Freemantle

    Published 2023-04-01
    Get full text
    Article

Search Tools: